医療/バイオ

★医療/バイオ産業カテゴリーの人気レポート・最新レポートはこちら★

スキンケアデバイスの世界市場規模・シェア・開発・成長・需要予測(2013~2023年):商品別(光・LED治療・フォトトリートメント、脂肪吸引、電気手術、レーザー治療、クライオセラピー、マイクロダーマブレージョン、皮膚鏡、生検装置、画像誘導システム)・用途別(セルライト除去、疾患診断・治療、脱毛、スキンタイトニング・体形矯正、若返り術)・地域別(米国、カナダ、ドイツ、イギリス、フランス、イタリア、スペイン、日本、中国、インド、オーストラリア、ブラジル、メキシコ、南アフリカ、イスラエル、サウジアラビア、アラブ首長国連邦)

2018年3月2日 // 0 Comments

The growth in the skincare devices market will be led by increasing cases of skin cancer and skin related disorders, technological advancements in skincare devices, increase in disposable income, rising demand for aesthetic procedures, and growing geriatric population.
Insights on market segments

The products used in the skincare devices market have been categorized as skin treatment devices and skin diagnostic devices. The market for the latter is expected to witness the fastest growth at a CAGR of 11.9% during the forecast period. This rising demand for skincare diagnostic devices can be attributed to the increasing prevalence of skin diseases, especially skin cancer, the diagnosis of which requires the use of these devices.

Skin treatment devices held the largest share in the skincare devices market in 2017. These devices include light/LED therapy and photorejuvenation, liposuction, electrosurgical, laser based, cryotherapy, microdermabrasion, and others. Light/LED therapy and photorejuvenation devices are estimated to capture the largest share of the skin treatment devices market in 2017. This is due to the worldwide growth in aging population, and increasing popularity of these devices as a way to fight acne, and many signs of aging. Laser based devices are expected to witness the fastest growth in demand, at a CAGR of 11.9% during the forecast period.

Cellulite reduction is the largest application category in the skincare devices market, which can be attributed to the high prevalence (80%–90%) of cellulite in post-pubertal female patients of all races and rising ageing population. On the other hand, the skin tightening and body contouring application category is expected to witness the fastest growth in demand for skincare devices, during the forecast period. The growth for skin tightening and body contouring services is driven by the increasing prevalence of obesity and growing number of people undergoing liposuction, who in turn require skin tightening for avoiding the problem of loose skin.

Asia-Pacific (APAC) is the fastest growing market for skincare devices

The skincare devices are expected to witness the fastest growth in demand in APAC, at a CAGR of 12.5% during the forecast period, owing to a large population, higher prevalence of skin diseases and obesity, and aging population in the region.

According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), people aged 65 years and above constituted approximately 11.4% of the population in 2013, and the count is estimated to increase by approximately 20% by 2050. The geriatric population is at a greater risk of skin cancer. According to the Skin Cancer Foundation, the majority of people diagnosed with melanoma are white men, above 55 years of age. Also, the elderly people generally face problems such as wrinkles, cellulite, loose skin, obesity and therefore, fueling the growth of the APAC skincare devices market.

Key Players Look to Technological Advancements for Market Expansion

The key players in the skincare devices industry are developing and launching new skincare devices that are equipped with latest technology, to gain a larger market share. For instance, in May 2017, Cutera Inc. launched truSculpt 3D, a new technology in body sculpting that offers up to 24% fat reduction in a single operation.

Some of the other key players operating in the skincare devices market include Allergan plc, Merz Pharma GmbH & Co. KGaA, Syneron Medical Ltd., Michelson Diagnostic Ltd., Lumenis Ltd., PhotoMedex Inc., Alma Lasers Ltd., Hologic Inc., Panasonic Corporation, Valeant Pharmaceuticals International Inc., and Beijing Toplaser Technology Co Ltd.

オッセオインテグレーションインプラントの世界市場規模・シェア・開発・成長・需要予測(2013~2023年):商品別(骨支持型義肢(脊椎固定、聴覚、上腕用義肢、下肢用義肢)歯科用インプラント(クラウン、インプラント、アバットメント))・素材別(メタリック、セラミクス、高分子)・エンドユーザー別(病院、歯科クリニック、ASC)・地域別(米国、カナダ、ドイツ、フランス、イギリス、日本、オーストラリア、インド、中国)

2018年3月2日 // 0 Comments

The growth in the market will be led by the increasing prevalence of spinal cord injuries, rise in the number of dental implant surgeries, reimbursement support by government and other organizations, rising number of trauma incidents, increasing hearing loss cases in the geriatric population, and spur in the funding for osseointegration research.
Insights on market segments

In terms of product type, the osseointegration implants market has been categorized as dental implants and bone-anchored prostheses. Dental implants are expected to witness a faster growth in demand, with a CAGR of 4.6% during the forecast period, owing to increasing prevalence of dental disorders and rising awareness about dental implants as a tooth-loss solution.

By material type, ceramic biomaterials are expected to project the fastest growth in demand with a CAGR of 4.2% during the forecast period. The growth of ceramic biomaterials is attributed to their tribological properties, biocompatibility, and aesthetic appearance. On the basis of end user, the osseointegration implants industry is categorized into hospitals, ambulatory surgical clinics (ASCs), and dental clinics. Due to the increasing number of dental implant procedures worldwide, the demand of osseointegration implants in dental clinics is expected to advance at a CAGR of 3.4% during the forecast period.

Asia-Pacific to exhibit fastest growth, with 4.8% CAGR during the forecast period

The osseointegration implants market in Asia-Pacific is expected to witness a significant growth during the forecast period. This growth is attributed to factors such as increasing development and research activities, rising disposable income that enables people to select appropriate treatment options, and access to modern healthcare facilities.

Technologically advanced countries such as Australia, are increasingly focusing on the development of implantable procedures for upper and lower limb amputees, enabling the manufacturers of osseointegration implants in bone-prostheses to grow significantly in this region. Moreover, the increasing dental tourism in countries such as India and Thailand have facilitated the growth of the osseointegration market for dental implants.

Major players launching innovative products to gain a larger market share

Globally, the key providers in the osseointegration implants industry are launching new products to gain a larger market share. For instance, in June 2017, DePuy Synthes Companies announced the launch of the VIPER and EXPEDIUM Fenestrated Screw Systems in the U.S. The system along with CONFIDENCE High Viscosity Spinal Cement would restore the integrity of the spinal column in patients with advanced stage spinal tumors.

Similarly, in January 2017, Integrum AB launched the new OPRA Implant System Platform G, which is to be used for transfemoral patients. The new platform is CE labeled and approved by the USFDA, which improves the mechanical performance of the system, simplifies the surgical procedure, and enhances osseointegration.

Some of the other key players operating in the osseointegration implants market include Zimmer Biomet Holdings Inc., Dentsply Sirona Inc., Danaher Corporation, The Straumann Group, Henry Schein Inc., Stryker Corporation, NuVasive, Inc., William Demant Holding A/S, Cochlear Ltd., and Medtronic plc.

ヘルスケアコグニティブコンピューティングの世界市場規模・シェア・開発・成長・需要予測(2014~2024年):技術別(自然言語処理(NLP)、機械学習、自動推論、情報検索)・展開モデル別(オンクラウド、オンプレミス)・エンドユーザー別(ヘルスケアプロバイダー、医薬品企業、医療機器企業、ヘルスケアペイヤー)、・地域別(米国、カナダ、イギリス、ドイツ、フランス、中国、日本、インド、ブラジル)

2018年3月2日 // 0 Comments

The growth in the healthcare cognitive computing market size will be led by increasing burden of chronic diseases, technological advancements in the healthcare industry encouraging the use of cognitive computing in healthcare, and rising adoption of third computing platforms.
Insights on market segments

The technologies used in the healthcare cognitive computing market have been categorized as natural language processing (NLP), machine learning, automated reasoning, and information retrieval, where NLP is expected to witness the fastest growth in demand, and is likely to garner a CAGR of 34.9% during the forecast period. This rising demand for the NLP technology can be attributed to its comprehensive evaluation process, which facilitates management of patient feedback and enables clinical staff to make informed decisions and respond to problems in real time. For instance, the U.S. based Intermountain Hospital uses the NLP technology to identify information associated with cardiac patients, cancer patients, and venous thromboembolism patients.

Cloud and on-premise are the two major types of deployment models used in the healthcare cognitive computing market. Globally, the cloud computing deployment model is estimated to acquire a larger market share, standing at 71.0% in 2017. This growth in the cloud computing deployment model is mainly attributed to its increasing use in the development of healthcare applications, such as electronic health records (EHRs), which are affordable and easily accessible to the healthcare providers to store and access data remotely and provide the necessary care without any delay.

Although cognitive computing is being increasingly used in healthcare by various healthcare professionals, it is the healthcare providers category that is expected to witness the fastest growth, as the end-user base, in the healthcare cognitive computing market during the forecast period. Healthcare providers have been estimated to lead the global market, occupying a 44.5% share in 2017. This growth in the demand for healthcare cognitive computing solutions by healthcare providers can be attributed to the increased usage of cognitive platforms by the providers for the detection and treatment of rare diseases. For instance, in October 2016, Rhön-Klinikum AG, a private hospital group in Germany, teamed up with IBM Corporation on a 12-month pilot project to help detect rare diseases and find their cure using the IBM’s Watson platform.

Asia-Pacific (APAC) is the fastest growing market for healthcare cognitive computing solutions

The APAC healthcare cognitive computing industry is expected to witness the fastest growth in demand, at a CAGR of 41.6%, during the forecast period, owing to rising geriatric population, increasing healthcare expenditure, growing public and private investments in the healthcare sector to cater to unmet medical needs, and burgeoning pharmaceutical industry in the region.

According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), people aged 65 years and above constituted approximately 11.4% of the population in 2013, and the count is estimated to increase by approximately 20% by 2050. Since the elderly generally need help in meeting their medication needs, including keeping track of their visits to the doctor, medication timings, exercise reminders, and dietary recommendations, there is ample scope for the healthcare cognitive computing market to flourish in the region.

Companies in the healthcare cognitive computing market are also increasingly getting involved in research and development to provide better healthcare solutions. For instance, in August 2016, IBM Watson aided in the detection of a rare form of leukemia in a patient in Japan. The cloud-based, AI-powered supercomputer of IBM is capable of cross-referencing and analyzing data from millions of oncology papers from research institutes all over the world.

Development of advanced healthcare computing solutions by key players, to gain a larger share

Globally, key players in the healthcare cognitive computing industry are developing advanced computing solutions for healthcare, to gain a larger market share. For instance, in November 2017, Nuance Communications Inc. unveiled Nuance AI Marketplace for Diagnostic Imaging at the Radiological Society of North America (RSNA) conference in Chicago. It is the first open platform for developers, data scientists, and radiologists to accelerate the development, deployment, and adoption of AI for medical imaging.

Some of the other key players operating in the healthcare cognitive computing market include IBM Corporation, Microsoft Corporation, Enterra Solutions, LLC, Intel Corporation, Alphabet Inc., Hewlett Packard Enterprise (HPE), CognitiveScale, Healthcare X.0 GmbH, and MedWhat.com Inc.

老視(老眼)治療薬のパイプライン分析

2018年3月1日 // 0 Comments

The study analyzed that the presbyopia therapeutics pipeline comprises nine drug candidates in different stages of development. Presbyopia is an age-related eye condition that causes visual impairment gradually. The disease has been described as “an irreversible optical failure, an unexplained evolutionary blunder that comes as a psychologic shock”. Though not incapacitating if corrected, presbyopia without optical correction results in an inability to perform once-effortless near tasks at a customary working distance without experiencing visual symptoms. The disease can result from the gradual decrease in the amplitude of accommodation.
Insights on pipeline segments

Various pharmaceutical companies such as Novartis AG, Allergan Plc., Janssen Global Services LLC, and Acucela Inc. are engaged in the development drug candidates for the treatment of presbyopia.

Positive clinical results of presbyopia drug candidates

Various pharmaceutical companies are developing drug candidates for the treatment of presbyopia, which have shown positive results in different stages of development. For instance, UNR844 showed a statistically significant difference to placebo in distant corrected near vision at all time points measured (from day 8) in the Phase I/II, placebo-controlled, proof-of-concept study carried out in 50 patients daily for 90 days with topical UNR844 and in 25 patients with placebo. At day 90, 82% of participants treated with UNR844 had 20/40 near vision (or 0.30 LogMAR) versus 48% in the placebo group. Near vision of 20/40 allows the majority of near vision tasks in most people.

Novel delivery systems and patented technologies for Presbyopia

Various pharmaceutical companies are involved in manufacturing drugs for the treatment of presbyopia. In January 2017, Alcon, the eye care division of Novartis AG, launched AcrySof IQ PanOptix Toric intraocular lens for presbyopia. The launch of the AcrySof IQ PanOptix Toric intraocular lens is a significant achievement in presbyopia treatment. Most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of presbyopia.

Some of the key players developing Novartis AG, Allergan Plc, and ORASIS Pharmaceuticals Ltd.

ニューロフィブロマトーシス(神経線維腫症)治療薬のパイプライン分析

2018年3月1日 // 0 Comments

The study analyzed that the Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development.
Insights on pipeline segments

Majority of the pipeline drug candidates are being developed to be administered by oral route. Celldex Therapeutics Inc. and Merck Co. Inc. are in the process of developing a monoclonal antibody drug candidate, CDX0158, and Pembrolizumab respectively for the treatment of NF. Lixte Biotechnology Holdings Inc. is in the process of developing two drug candidates, in the Pre-Clinical stage of development for the treatment of neurofibromatosis (NF). In September 2016, the USFDA granted Orphan Drug Designation to BXCL101, a drug candidate of BioXcel Therapeutics Inc. for the treatment of NF type 2.

Unmet medical needs driving the neurofibromatosis therapeutics pipeline

Since there is no treatment available for NF, the growing medical needs of the people suffering from the disease are driving its therapeutics pipeline growth. High rate of recurrence/progression of the disease and poor long-term benefit of surgery can be viewed as a limitation of this treatment option.

Positive clinical trial results propelling the growth of the pipeline therapeutics of the Neurofibromatosis

The drugs being developed by the different pharmaceutical companies demonstrated positive clinical trial results which in-turn increasing their further development. For instance, In June 2014, Array BioPharma Inc. announced positive results of Phase I/II, combination of binimetinib and LEE011. Selumetinib being developed by the AstraZeneca plc. And it met primary endpoint as confirmed partial responses (tumor volume decreases from baseline of ≥20%) in 17 of the 24 children (71%) in Phase I study.

Some of the key players developing drugs for the treatment of neurofibromatosis include Novartis AG, AstraZeneca Plc, Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc, BioXcel Therapeutics, Inc.

便秘治療薬のパイプライン分析

2018年3月1日 // 0 Comments

The study analyzed that the constipation therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Most of the drugs in pipeline for the treatment of constipation are in late stage of development. Constipation is a common functional gastrointestinal (GI) disorder that is most prevalent in the elderly and female population. According to the journal Clinical Interventions in Aging, published in 2015, the prevalence of the disease is around 20% in the world population, varying between 2% and 27% in different countries. The economic impact of chronic constipation is significant in the U.S., with around 100,000 constipation-related hospitalizations annually.
Insights on pipeline segments
Pharmaceutical companies are developing various drug candidates for the treatment of constipation in different stages of development including Filed, Phase III, Phase II, Phase I, and Pre-clinical. Albireo Pharma Inc. is in the process of developing a drug candidate, which is in the Filed stage of development, for treating constipation. There are small molecules as well as peptide type drug candidates in development for the treatment of constipation. A majority of the constipation therapeutics pipeline drugs are being developed as an oral dosage form.

Increasing prevalence of GI disorders boosting the growth of constipation pipeline

There has been considerable increase in the prevalence of GI disorders, such as non-alcoholic fatty liver disease, diabetes, pancreatitis, and acidity, in people. These problems have a huge impact on the digestion process, which, in turn, causes constipation. It has also been observed that synthetic foods too cause indigestion in people, which results in constipation. Thus, unhealthy dietary behavior too increases the chances of occurrence of constipation. Thus, increasing prevalence of GI disorders contributes as one of the key drivers for the development of drugs to treat constipation.

Technological advancements for the development of drug candidates to treat constipation

With advances in technology, many pharmaceutical companies are leveraging new and improved technologies for the development of drug candidates to treat constipation. These technologies are helpful in the development of drugs as either combination therapies or single-agent therapies. They also allow development of specific targeted therapies with better drug delivery. For instance, Ardelyx Inc. has developed a unique platform that enables to discover targets in the GI tract, which control health and disease processes to optimize drug candidates and to understand their mechanisms of action.

Some of the players involved in the development of drug candidates for the treatment of constipation are Nordic Life Science Pipeline Inc., Enterin Inc., and Yuhan Corporation Ltd.

mTOR阻害薬のパイプライン分析

2018年3月1日 // 0 Comments

The mechanistic/mammalian target of rapamycin (mTOR) is a serine threonine protein kinase, that belongs to the phosphatidylinositol-3-kinase-related kinase family. Molecules in this family have more than 2,500 amino acids, and they harbor a kinase domain at their C-terminals. It has been observed that the increasing prevalence of cancer along with its high healthcare cost, globally, has been driving the growth of mTOR inhibitors pipeline. For instance, the number of people living beyond cancer diagnosis reached around 14.5 million in 2014 and is expected to increase to 19 million, by 2024. In 2010, approximately $125 million was spent on cancer care in the U.S., and it is expected to reach $156 million, by 2020.
Other factors strengthening the mTOR inhibitors pipeline include smoking, obesity unhygienic food, and allergy. The study analyzed that mTOR inhibitors therapeutics pipeline comprises approximately 30 drug candidates in different stages of development.

Insights on pipeline segments

According to the research findings, most of the drug candidates that act as mTOR inhibitors are being developed as small molecules, further supported by the fact that small molecules have several advantages such as it can be manufactured with production rate higher than any other molecule types.

Positive Clinical Results of mTOR Inhibitors Therapeutics Candidates

The positive clinical results of mTOR inhibitors drug candidates is a key factor driving the pipeline growth. For instance, F. Hoffman-La-Roche AG has developed a drug candidate, ipatasertib, that acts as mTOR inhibitors. The Phase II clinical results (Study ID: NCT02162719) of the drug candidate were published in the Lancet Oncology journal. It has been observed that progression-free survival was longer in patients who received ipatasertib as compared in those who received placebo.

Technological Advancements for mTOR Inhibitors Therapeutics Drug Development

Most of the companies are developing innovative technologies for the synthesis or production of mTOR inhibitors. For instance, PHusis Therapeutics Inc. is using its computational modeling platform namely, PHuDock, that identify inhibitors of proteins which promotes the growth of cancer cells. Using PHuDock, X-ray structural information and surface plasmon resonance spectroscopic measurements of selected drug-like molecules, PHusis is rapidly and efficiently identifying agents involving toxicity studies, that selectively inhibit the activity of a number of these cancers driving proteins. PHuDock is applied to lead identification and optimization, as well as to predict the compounds off-target properties and toxicity, therefore delivering novel and highly effective agents with low toxicity.

These technologically advanced platforms enable the players in the pipeline to develop effective new therapies rapidly, that are cost effective and potentially have lower risk of toxicity, and relative to traditional approaches. Thus, these technological advancements act as a key driver for the pipeline growth.

Some of the key players involved in the development of mTOR inhibitors therapeutics include F. Hoffman-La-Roche AG, Pfizer Inc., and resTORbio Inc.

メンブレンクロマトグラフィーの世界市場予測(~2022年):商品別(消耗品(カプセル・カートリッジ)、シリンジフィラー、メンブレンフィルター、スピンカラム)、付属品)、技術別(イオン交換、アフィニティ(陰イオン)、疎水性相互作用)、オペレーション形態別(フロースルー式)

2018年2月27日 // 0 Comments

“The global membrane chromatography market is projected to grow at a CAGR of 18.1%.”
The global membrane chromatography market is expected to reach USD 290.6 million by 2022 from USD 126.6 million in 2017, at a CAGR of 18.1%. Growth in this market can primarily be attributed to factors such as increasing demand for biopharmaceuticals, increasing R&D expenditure in the biopharmaceutical industry, significant benefits of membrane chromatography over conventional chromatography methods, and increasing regulatory scrutiny on the cleaning validation of downstream purification processes. However, the limited use of membrane chromatography in large-scale manufacturing is expected to restrain the growth of this market during the forecast period.

“The ion exchange membrane chromatography segment is expected to account for the largest share in 2017.”
Based on techniques, the membrane chromatography market is segmented into ion exchange membrane chromatography, affinity membrane chromatography, and hydrophobic interaction membrane chromatography. The ion exchange membrane chromatography segment is expected to account for the largest share of the global membrane chromatography market in 2017. The large share of this segment can be attributed to its wide applications in antibody polishing and virus purification due to the advantages associated with ion exchange membrane chromatography, such as scalability, robustness, disposable nature, high throughput, rapid processing, reduced buffer consumption, and a validation-free environment.
Based on product, the consumables segment is expected to dominate the market in 2017
In 2017, the membrane chromatography consumables segment is expected to account for the largest share of the global market. Growth in this segment can primarily be attributed to the increasing use of capsules and cartridges for purification applications in biomanufacturing and lab-scale production and process development processes.
“North America is expected to account for the largest share during the forecast period.”
By region, North America is expected to account for the largest share of the global membrane chromatography market. This large share can be attributed to the increasing demand for biopharmaceuticals and rising R&D expenditure by biopharmaceutical companies in North America. Europe is expected to account for the second-largest share of the membrane chromatography market.
Break-up profile of primaries:
• By Company Type- Tier 40%, Tier 30%, and Tier 30%
• By Designation-C-level-27%, D-level-18%, and Others-55%
• By Region-North America-50%, Europe-20%, Asia Pacific-20%, and RoW-10%
The key players in the global membrane chromatography market are Sartorius (Germany), GE Healthcare (US), Danaher (US), Merck Millipore (US), and 3M (US).
Research Coverage:
The membrane chromatography market in this report is segmented by product, technique, operation mode, and region. The study tracks and analyzes competitive developments such as product launches, collaborations, agreements, partnerships, and acquisitions, and profiles key players and core competencies in the membrane chromatography market.
Reasons to buy this report:
The report provides insights on the following pointers:
Market Penetration: Comprehensive information on portfolios offered by the top players in the global membrane chromatography market. The report analyzes the market by product, technique, operation mode, and region

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global membrane chromatography market

Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for membrane chromatography products across regions

Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global membrane chromatography market

Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global membrane chromatography market

体内 (in vivo) 毒性の世界市場予測(~2022年):商品別(器機、消耗品(動物モデル、試薬と道具))、テストタイプ別(慢性、亜慢性)、毒性評価項目別(免疫毒性、全身毒性、発生・生殖毒性)、テスト施設別(外部委託、社内)

2018年2月27日 // 0 Comments

“The global in vivo toxicology market is projected to grow at a CAGR of 6.9%.”
The in vivo toxicology market is expected to reach USD 6.14 billion by 2022 from an estimated USD 4.40 billion in 2017, at a CAGR of 6.9%. The key factors driving the growth of this market include, increasing pharmaceutical R&D activities, mandatory government regulations for animal testing, innovations in animal models, and the development of exclusive in vivo toxicology tests. On the other hand, alternative methods to animal testing and disadvantages associated with animal toxicology testing likely to restrain the growth of this market.

“The instruments segment is expected to grow at the highest CAGR during the forecast period”
On the basis of product, the in vivo toxicology market is segmented into consumables and instruments. The consumables segment is further divided into reagents & kits and animal models. The instruments segment is expected to grow at the highest rate during the forecast period. The growth of this segment can be attributed to the increasing research on biological samples (such as blood and urine) using bioanalytical equipment.

“Chronic toxicity testing holds the largest share in the global in vivo toxicology market by testing type”
Based on testing type, the global in vivo toxicology market is segmented into acute, sub-acute, sub-chronic, and chronic toxicity testing. In 2017, chronic toxicity testing segment is estimated to hold the largest share in the global in vivo toxicology market. The large share of this market is attributed to the high cost of in vivo testing for more than 90 days, maintaining the animals, quality of tests, and the long duration of the tests performed.

“The immunotoxicity segment is expected to grow at the highest CAGR during the forecast period.”
On the basis of toxicity endpoint, the global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental and reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2017, the immunotoxicity segment is expected to account for the largest share in the in vivo toxicology market, this segment is also expected to grow at the highest CAGR during the forecast period. Rising demand for the development of biologics for autoimmune diseases and cancer and the increasing growth of biosimilars in oncology are driving the growth of this segment.

“China to witness the highest growth in the APAC region during the forecast period (2017-2022)”
In the APAC region, China is expected to witness the highest growth during the study period. The rising R&D funding and collaborations; initiatives taken by the Chinese government to promote life science research; and the strong trend of commercialization of biotechnology research are contributing to the growth of in vivo toxicology market in China.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–29%, Tier 2–35% and Tier 3–36%
• By Designation – C-level–39%, Director Level–35%, Others–26%
• By Region – North America–42%, Europe–36%, Asia Pacific–13%, RoW–9%

The major players in the global in vivo toxicology market are Thermo Fisher (US), Danaher (US), Charles River (US), Covance (LabCorp), and The Jackson Laboratory (US).
Research Coverage:
The report analyzes the in vivo toxicology market and aims at estimating the market size and future growth potential of this market based on various aspects such as products, testing type, toxicity endpoint, testing facility and region. The report also includes the competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in-turn would help them, garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by key players in the global in vivo toxicology market. The report analyzes the global in vivo toxicology market by product, testing type, toxicity endpoint, testing facility, and region
• Product and Service Innovation: Detailed insights on upcoming trends and product and service launches in the global in vivo toxicology market
• Market Development: Comprehensive information about the lucrative emerging markets by product, testing type, toxicity endpoint, testing facility, and region
• Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global in vivo toxicology market
• Competitive Assessment: In-depth assessment of market shares and growth strategies of leading players in the global market

マイクロプレートシステムの世界市場予測(~2022年):商品別(リーダー (マルチモード (ハイブリッド)・シングルモード)・ディスペンサー・ソフトウェア)、用途別(研究、臨床診断)、エンドユーズ別(バイオテクノロジー、医薬品、病院、診断ラボ)

2018年2月27日 // 0 Comments

“The global microplate systems market projected to grow at a CAGR of 4.0%.”
The global microplate systems market is expected to reach USD 996.9 million by 2022 from USD 820.3 million in 2017 at a CAGR of 4.0%. This market is experiencing significant growth due to increasing R&D expenditure in the pharmaceutical industry, increasing focus on miniaturization, technological advancements, and growing prevalence of diseases.

“Microplate Readers are expected to grow at the highest CAGR during the forecast period.”
Based on product and service, the market is segmented into microplate readers, microplate pipetting systems and dispensers, microplate washers, and other products. The microplate readers segment is expected to hold the largest share of the market in 2017 and projected to register the highest CAGR during the forecast period. High demand for these systems due to increasing number of research activities are the key factors driving the growth of this segment.

“Biotechnology and pharmaceutical companies is expected to dominate the market during the forecast period.”
Based on end user, the market is segmented into biotechnology and pharmaceutical companies, hospitals and diagnostic laboratories, and research and academic institutes. The biotechnology and pharmaceutical companies segment is estimated to hold the largest share the microplate systems market in 2017. It is projected to register the highest growth during the forecast period due to increasing government support in the form of funding for biotech and pharma research.

“Asia Pacific to witness the highest growth during the forecast period.”
In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia Pacific is expected to register the highest CAGR during the forecast period. This can be attributed to factors such as the growing focus on research-related funding activities by government organizations, increasing healthcare investments, increasing ageing population, and increasing prevalence of diseases.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 30%; Tier 2 – 42%; Tier 3 – 28%
• By Designation: C-level- 25%; D-level- 45%; Others- 30%
• By Region: North America-48%; Europe-29%; Asia Pacific-20%; Latin America- 19%, Rest of the World-4%

List of companies profiled in the report
• BioTek (US)
• Danaher (US)
• PerkinElmer (US)
• Tecan (Switzerland)
• Thermo Fisher (US)
• BMG LABTECH (Germany)
• BERTHOLD (Germany)
• Agilent (US)
• Bio-Rad (US)
• Promega (US)
• Biochrom (UK)
• Corning (US)
• Lonza (Switzerland)
• Rayto (China)
• Mindray (China)
Research Coverage:
The report provides an overview of the microplate systems market. It aims at estimating the market size and future growth potential of this market across different segments such as product, application, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall microplate systems market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

ガイドワイヤーの世界市場予測(~2022年):材料別(ニチノール、ステンレス鋼、ハイブリッド)、商品別(外科、診断(親水性、疎水性))、用途別(循環器、血管、神経、GIT、ENT、泌尿器、腫瘍)、エンドユーザー別(病院、ASC)

2018年2月27日 // 0 Comments

The guidewires market projected to grow at a CAGR of 4.8%
The global guidewires market is projected to reach USD 764.0 million by 2022 from USD 605.2 million in 2017, at a CAGR of 4.8%. The growth witnessed by guidewires is mainly driven by growing target disease incidence, continuous product commercialization by major manufacturers and favorable medical reimbursements for guidewires in developed countries. The government initiatives to control the burden of healthcare-associated infections (HAIs) in developed countries and the increasing healthcare expenditure across emerging markets are also driving the growth of the market. However, high cost of surgical guidewires, spending cuts & excise duties on medical devices and dearth of skilled surgeons for minimally invasive surgeries are the key challenges faced by a majority of the guidewires manufacturers across the globe.
“The hybrid guidewires segment is poised to be the fastest-growing during the forecast period.”
On the basis of material, the global guidewires market is segmented into nitinol guidewires, stainless steel guidewires, and hybrid guidewires. The hybrid guidewires segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to rising adoption among medical professionals owing to their technological and procedural advantages, growing awareness among surgeons about the clinical benefits of these guidewires, and the evolving reimbursement scenario for target procedures across key healthcare markets.
“The cardiology applications segment is poised to be the fastest-growing during the forecast period.”
On the basis of application, the global guidewires market is segmented into cardiology, vascular, neurology, urology, gastroenterology, oncology, and otolaryngology. The cardiology applications segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the rising adoption of guidewires among cardiologists owing to procedural and technical benefits offered by nitinol materials used for manufacturing cardiology guidewires.

“Asia Pacific is expected to register the highest growth rate during the forecast period.”
Geographically, the guidewires market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The highest CAGR for the APAC guidewires market can be attributed to the rising adoption of guidewires due to their decreasing costs (owing to the increase in localized manufacturing and strengthening of distribution networks of key product manufacturers) and increasing healthcare expenditure across key APAC countries.

Breakdown of supply-side primary interviews: by company type, designation, and region:
• By Company Type – Tier 1 – 25%, Tier 2 – 30% and Tier 3 – 45%
• By Designation – C level – 26%, Director level – 30%, Others – 44%
• By Region – North America – 34%, Europe – 26%, APAC – 23%, RoW – 17%

The global guidewires market is competitive, with a large number of global and local players. In 2016, the market was dominated by Boston Scientific (US), Medtronic (Ireland), Abbott (US), Cook Group (US), and Terumo (Japan). Product launches, market expansions, strategic acquisitions, partnerships, agreements & collaborations were the major strategies adopted by market players to achieve growth in the market.

Research Coverage
This report studies the guidewires market based on material, product, application, and end user. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for the market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.

Reasons to Buy the Report:
From an insights perspective, this research report has focused on various levels of analysis—industry trends, market share analysis of top players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the guidewires market, and high-growth regions and countries and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms garner greater market shares. Firms purchasing the report could use any one or a combination of the belowmentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on product portfolios offered by the major players in the guidewires market. The report analyzes the guidewires market based on material, product, application, end user, and region
• Product Development: Detailed insights on the research and development activities and product launches in the guidewires market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various guidewires across geographies.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the guidewires market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the guidewires market

オリゴヌクレオチド合成の世界市場予測(~2022年):商品別(プライマー、プローブ、リンカー、アダプター、カスタムオリゴ、試薬、機器)、用途別(PPCR、DNA、RNAi、研究、治療)、エンドユーザー別(学術研究機関、医薬品、バイオテクノロジー)

2018年2月27日 // 0 Comments

“The global oligonucleotide synthesis market projected to grow at a CAGR of 10.9%.”
The global oligonucleotide synthesis market is expected to reach USD 2.46 billion by 2022 from USD 1.47 billion in 2017 at a CAGR of 10.9%. This market is experiencing significant growth due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques.
Growth in this market is mainly driven the increasing R&D expenditure by pharmaceutical and biotechnology companies, rising demand for synthesized oligonucleotides from the growing field of molecular diagnostics, rising venture capital investments, and increasing demand for synthetic genes. However, the price erosion of synthesized oligos and lack of regulations for therapeutic oligos are some factors that may hinder the growth of this market.

“Synthesized oligonucleotides are expected to grow at the highest CAGR during the forecast period.”
Based on product, the market is segmented into synthesized oligonucleotides, reagents, and equipment. The synthesized oligonucleotides segment is expected to grow at the highest CAGR during the forecast period The increasing number of applications of synthesized oligonucleotides in research, diagnostics, and therapeutics is a key market driver in this segment. The rising availability and demand for custom oligos also contribute to the growth of the synthesized oligonucleotides market.

“The research segment is expected to hold the largest share of the market in 2017.”
Based on application, the market is segmented into research, diagnostics, and therapeutics. The research segment is estimated to hold the largest share of the oligonucleotide synthesis market in 2017. The market growth for research applications is mainly driven by the developments in the fields of gene synthesis and NGS. Oligos are widely used in technologies such as PCR, qPCR, gene synthesis, isothermal nucleic acid amplification technology (INAAT), microarray, hybridization, DNA sequencing, and next-generation sequencing (NGS).

“Academic research institutes are expected to dominate the market during the forecast period.”
Based on end user, the market is segmented into academic research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, and other end users. The academic research institutes segment is expected to dominate the market during the forecast period. With the increasing funding pouring into institutes to conduct research, the demand for oligonucleotides is bound to increase. To meet this need, companies are launching products and entering into agreements with different research institutes to supply oligonucleotides for research purposes. For instance, in August 2015, Eurofins Genomics launched NGS tests for the identification of non-targeted microorganisms, including 16S Microbiome Profiling for academia and research.

“APAC to witness the highest growth during the forecast period.”

In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia Pacific is expected to register the highest CAGR during the forecast period. This can be attributed to factors such as the growing availability of synthesized oligos, along with an increase in R&D funding and activities in the APAC region. The increasing focus of prominent players on APAC is also supporting market growth in the region.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 36%; Tier 2 – 46%; Tier 3 – 18%.
• By Designation: C-level- 26%; D-level- 45%; Others- 29%.
• By Region: North America-41%; Europe-31%; Asia Pacific-20%; Latin America- 5%, Middle East and Africa-3%

List of companies profiled in the report
• Agilent Technologies (US)
• ATDBio (UK)
• Bio-Synthesis (US)
• BioAutomation (US)
• LGC Biosearch Technologies (US)
• Eurofins Genomics (Germany)
• Eurogentec (Belgium)
• GeneDesign (Japan)
• GE Healthcare (US)
• GenScript (US)
• Integrated DNA Technologies (IDT) (US)
• Nitto Denko Avecia (US)
• Thermo Fisher Scientific (US)
• TriLink Biotechnologies (US)
• Sigma-Aldrich Corporation (Sigma-Aldrich) (US) (part of Merck KGAA (Germany)
Research Coverage:
The report provides an overview of the oligonucleotide synthesis market. It aims at estimating the market size and future growth potential of this market across different segments such as product, application, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall oligonucleotide synthesis market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

CROサービスの世界市場予測(~2023年):タイプ別(創薬研究、CMC、前臨床、臨床研究、ラボサービス)、治療領域別(腫瘍、CNS、心臓血管)、エンドユーザー別(医薬品と医療機器)

2018年2月27日 // 0 Comments

“The Contract Research Organization (CRO) services market is projected to grow at a CAGR of 7.6% between 2018 and 2023.”
The CRO services market is expected to reach USD 56.34 billion by 2023 from USD 39.13 billion in 2018, at a CAGR of 7.6%. Increased outsourcing of R&D activities and increasing number of clinical trials are some of the major factors driving the growth of this market. However, intense competition in the CRO services market is one of the major challenges for the players operating in the CRO services market.
“Laboratory services segment to witness the highest growth rate during the forecast period.”
Among the CRO services, the laboratory services segment is expected to register the highest CAGR during the forecast period. The high growth of this segment is attributed to the increasing number of pipeline drugs and growing outsourcing of laboratory services by pharmaceutical and biopharmaceutical companies.
“Oncology segment to grow at the highest CAGR from 2018 to 2023.”
Oncology segment is expected to register the highest CAGR during the forecast period. The increasing number of clinical trials and rising prevalence of cancer worldwide are the major factors supporting its growth during the forecast period.
“APAC to witness the highest growth rate during the forecast period.”
The Asia Pacific region is expected to witness the highest CAGR during the forecast period, owing the rapid growth in the pharmaceutical and biopharmaceutical industry, low cost of clinical trials, rising number of CROs, and favorable government policies in the region.
Break of primary participants:
• By Company Type – Tier 1: 21%, Tier 2–26%, and Tier 3–53%
• By Designation – C Level: 32%, Director Level: 26%, and Others: 42%
• By Region – North America: 26%, Europe: 35%, Asia Pacific: 20%, Latin America: 11%, and the Middle East & Africa: 8%
Research Coverage:
The report analyzes the various CRO services and their adoption patterns in the market. It aims at estimating the market size and future growth potential of the global CRO services market for different segments such as type, therapeutic area, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use any one or combination of the below-mentioned strategies for strengthening their market positions.
The report provides insights on the following pointers:
 Market Penetration: Comprehensive information on the service portfolios offered by the top players in the CRO services market
 Service Launch/Innovation: Detailed insights on new service launches in the CRO services market
 Market Development: Comprehensive information about lucrative emerging markets, by type, therapeutic area, end user, and region
 Market Diversification: Exhaustive information about new services, growing geographies, recent developments in the CRO services market
 Competitive Assessment: In-depth assessment of growth strategies, services, and manufacturing capabilities of leading players in the CRO services market

血漿分画製剤の世界市場予測(~2023年):商品別(IVIG(静注免疫グロブリン)、アルブミン、第VIII因子、フォンヴィレブラント因子、PCC (プロトロンビン複合体製剤)、プロテアーゼ阻害剤)、用途別(免疫療法、血液疾患、救命治療、リウマチ)、エンドユーザー別(病院、クリニック、学術研究機関)

2018年2月27日 // 0 Comments

The plasma fractionation market is projected to reach to USD 29.50 billion by 2023 from an estimated USD 21.23 billion in 2018. The growing geriatric population across the globe, increasing use of immunoglobulins in various therapeutic areas, growing prevalence of respiratory diseases and uptake of alpha-1-antitrypsin, and increase in plasma collection are the factors driving this market. However, the emergence of recombinant alternatives, high cost of plasma products, and limited reimbursement may hinder the growth of this market.

The protease inhibitors segment is expected to grow at the highest CAGR during the forecast period
On the basis of product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The protease inhibitors segment is expected to witness the highest growth during the forecast period. The high growth of this segment is primarily attributed to the increasing prevalence of alpha-1 antitrypsin deficiency and increasing number of various respiratory diseases.

The pulmonology segment is projected to witness the highest growth during the forecast period
Based on the application, the plasma fractionation market is classified into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. The pulmonology segment
is expected to grow at the highest CAGR during the forecast period. This can largely be attributed to the increasing use of immunoglobulins and protease inhibitors in the treatment of various respiratory diseases such as AATD and COPD, asthma, and respiratory tract infections.

The hospitals and clinics segment is expected to grow at the highest CAGR during the forecast period
On the basis of type of end user, the market is segmented into hospitals & clinics, clinical research laboratories, and academic institutes. During the forecast period, the hospitals & clinics segment is expected to grow at the highest CAGR. The high growth of this segment can be attributed to the increasing adoption of plasma products in the treatment of various immunological, neurological, and bleeding disorders; large patient pool treated in hospitals; growing number of hospitals & clinics across the globe; and increasing number of collaborations between the manufacturers of plasma products and hospitals.

Asia Pacific to witness the highest growth during the forecast period
Asia Pacific is expected to witness the highest growth during the forecast period (2018 to 2023). The region’s large geriatric population, large population, improving healthcare infrastructure, increasing incidences of immunological and bleeding diseases, increasing focus diagnosis and prophylactic treatment, and increasing awareness about technologically advanced products are driving the growth of this market.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–46%, Tier 2–33% and Tier 3–21%
• By Designation – C Level–43%, Director Level–35%, Others–22%
• By Region – North America–34%, Europe–26%, Asia Pacific–24%, Latin America–12%, Middle East and Africa- 4%
Some of the major market players in the plasma fractionation market are CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), Bio Product Laboratory (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).
Research Coverage:
The report analyzes the plasma fractionation market and aims at estimating the market size and future growth potential of this market based on various segments such as product, application, end user, and region. The report also includes a volume data analysis for various plasma products across the globe and a competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global plasma fractionation market. The report analyzes the global plasma fractionation market by product, application, end user, and region.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global plasma fractionation market.
• Market Development: Comprehensive information on the lucrative emerging markets by product, application, end user, and region.
• Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global plasma fractionation market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of leading players in the global plasma fractionation market.

肩関節形成術の世界市場2018-2022:総肩関節、部分的肩関節、人口肩関節

2018年2月26日 // 0 Comments

About Shoulder Arthroplasty
The shoulder joint is a highly mobile joint. It comprises four joints, namely the sternoclavicular joint, scapulothoracic joint, acromioclavicular joint, and glenohumeral joint. Shoulder arthroplasty is a surgical procedure for partial or total replacement of the glenohumeral joint by a prosthetic implant. The surgery is conducted to relieve arthritic shoulder pain and fix severe joint damage due to injury.

Technavio’s analysts forecast the global shoulder arthroplasty market to grow at a CAGR of 6.12% during the period 2018-2022.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global shoulder arthroplasty market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Shoulder Arthroplasty Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• DePuy Synthes
• Integra LifeSciences
• Smith & Nephew
• Wright Medical Group
• Zimmer Biomet

[Market driver]
• Growing prevalence of arthritis coupled with increasing geriatric population
• For a full, detailed list, view our report

[Market challenge]
• High cost of technological development
• For a full, detailed list, view our report

[Market trend]
• Growing utilization of robotics in surgeries
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

1 2 3 28